GDPR Compliance

We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

Vitrolife AB Interim report Q3, 2024: Improved growth with solid margins

Toor News Staff ~ 11/8/2024
GOTHENBURG , Sweden , Oct. 24 , 2024 /PRNewswire/ -- Third quarter Sales of SEK 867 ( 848 ) million , an increase of 7 % in local currencies and 2 % in SEK . Sales per region , in local currencies was +9 % in EMEA , +2 %

GOTHENBURG, Sweden, Oct. 24, 2024 /PRNewswire/ -- 

Third quarter 

  • Sales of SEK 867 (848) million, an increase of 7% in local currencies and 2% in SEK.
  • Sales per region, in local currencies was +9% in EMEA, +2% in Americas and +9% in APAC.
  • Sales per business area, in local currencies was +13% in Consumables, +11% in Technologies and 0% in Genetics.
  • Gross margin increased to 58.6% (55.7).
  • Operating income before depreciation and amortisation (EBITDA) was SEK 289 (287) million, giving an EBITDA margin of 33.4% (33.9).
  • Operating cash flow decreased to SEK 206 million (214).
  • Net income was SEK 116 (122) million, resulting in earnings per share of SEK 0.85 (0.90).  

First nine months

  • Sales of SEK 2,650 (2,607) million, an increase of 4% in local currencies and 2% in SEK.
  • Sales per region, in local currencies was +6% in EMEA, -2% in Americas and +7% in APAC.
  • Sales per business area, in local currencies was +10% in Consumables, +20% in Technologies and -7% in Genetics.
  • Gross margin increased to 58.6% (56.1).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 888 (842) million, giving an EBITDA margin of 33.5% (32.3).
  • Operating cash flow increased to SEK 640 million (586).
  • Net income was SEK 375 (328) million, resulting in earnings per share of SEK 2.76 (2.42).

Gothenburg, October 24, 2024VITROLIFE AB (publ)Bronwyn Brophy O´Connor, CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 24-10-2024 08:00 CET.

Contact: Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q3--2024--improved-growth-with-solid-margins,c4055545

The following files are available for download:

SOURCE Vitrolife AB

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3

440k+Newsrooms &Influencers icon1

9k+Digital MediaOutlets icon2

270k+JournalistsOpted In Originally published at https://www.prnewswire.com/news-releases/vitrolife-ab-interim-report-q3-2024-improved-growth-with-solid-margins-302285557.html Images courtesy of https://pixabay.com

Photo by Wulfrano Del Angel via Pexels

More from Medicine